Maiara Rodrigues Salvador
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maiara Rodrigues Salvador has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra de Paula Carli
Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil
2 shared publications - Caio César Souza Alves
Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil
2 shared publications - Sandra Bertelli Ribeiro Castro
Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil
2 shared publications - Alessa Sin Singer Brugiolo
Universidade Federal de Juiz de Fora
1 shared publication - Ana C. F. Sperandio
Faculdade de Medicina, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Teófilo Otoni 39803-371, MG, Brazil
1 shared publication - Angelo Marcio Leite Denadai
Universidade Federal de Juiz de Fora
1 shared publication
Latest Publications
- Open Access
- 30 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6854
High-Intensity Interval Training Snacks Improve Experimental Autoimmune Encephalomyelitis
Several studies have shown that physical activity is associated with increased life expectancy and the prevention of chronic and neurodegenerative diseases. This study aimed to evaluate the impact of high-intensity interval training (HIIT) on the progression of an experimental model of multiple sclerosis. For this purpose, the murine model of experimental encephalomyelitis (EAE) was used in female C57BL/6 mice, divided into four groups: negative control (CN), positive control (EAE), HIIT once a day (1-HIIT), and HIIT snacks, three times a day (3-HIIT). The clinical score results demonstrated a significant reduction in the clinical score in mice subjected to 3-HIIT, confirmed by analyses of pro- and anti-inflammatory cytokines and histological analyses. These results provided solid evidence for the potential of HIIT protocols, especially 3-HIIT, to reprogram an autoimmune response in the CNS in mice with the EAE model, favoring a neuroprotective and immunoregulatory environment—evidence that may drive clinical research.
- 30 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6854
Open AccessHigh-Intensity Interval Training Snacks Improve Experimental Autoimmune Encephalomyelitis
Several studies have shown that physical activity is associated with increased life expectancy and the prevention of chronic and neurodegenerative diseases. This study aimed to evaluate the impact of high-intensity interval training (HIIT) on the progression of an experimental model of multiple sclerosis. For this purpose, the murine model of experimental encephalomyelitis (EAE) was used in female C57BL/6 mice, divided into four groups: negative control (CN), positive control (EAE), HIIT once a day (1-HIIT), and HIIT snacks, three times a day (3-HIIT). The clinical score results demonstrated a significant reduction in the clinical score in mice subjected to 3-HIIT, confirmed by analyses of pro- and anti-inflammatory cytokines and histological analyses. These results provided solid evidence for the potential of HIIT protocols, especially 3-HIIT, to reprogram an autoimmune response in the CNS in mice with the EAE model, favoring a neuroprotective and immunoregulatory environment—evidence that may drive clinical research.
- 1 April 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (4) , 1-11
Ursolic acid derivatives improved clinical signs of experimental autoimmune encephalomyelitis by modulating central nervous system inflammation
The immunopathogenesis of multiple sclerosis (MS) involves the activation of T lymphocytes, leading to progressive axonal loss and brain atrophy. Ursolic acid (AU) has been widely used as an herbal medicine, with the ability to inhibit the production and secretion of cytokines and may influence the differentiation of CD4 + helper cells. In this study, we aimed to investigate the immunomodulatory effects of ursolic acid derivatives (methyl 3β-hydroxyurs-12-en-28-oate (AUD1) and methyl 3β-acetoxyurs-12-en-28-oate (AUD2)) in a model of experimental autoimmune encephalomyelitis (EAE). EAE was induced by subcutaneous immunization of myelin oligodendrocyte glycoprotein peptide (MOG35−55) in C57BL/6 mice. On the 15th day post-induction (dpi), the mice were treated with AU, AUD1, or AUD2 (50 mg/kg intraperitoneally per day) for six days. Clinical signs were monitored until 21 dpi, and parameters were assessed in the spinal cord, lymph nodes, and brain at 21 dpi. The results showed that both derivatives similarly attenuated the clinical signs of EAE and reduced inflammation and demyelination in the spinal cord. In addition, they reduced the number of pro-inflammatory cells in the brain, the level of IL-1β, TNF, and IFN-γ in the spinal cord, and, in the periphery, promoted the regulation of pro-inflammatory cells. In conclusion, regulating cells in the periphery and reducing the number of pro-inflammatory cells in the CNS, with AUD1 and AUD2, culminated in the efficacy of the clinical parameters presented in EAE, suggesting a therapeutic potential for treating MS.
- 1 April 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (4) , 1-11
Ursolic acid derivatives improved clinical signs of experimental autoimmune encephalomyelitis by modulating central nervous system inflammation
The immunopathogenesis of multiple sclerosis (MS) involves the activation of T lymphocytes, leading to progressive axonal loss and brain atrophy. Ursolic acid (AU) has been widely used as an herbal medicine, with the ability to inhibit the production and secretion of cytokines and may influence the differentiation of CD4 + helper cells. In this study, we aimed to investigate the immunomodulatory effects of ursolic acid derivatives (methyl 3β-hydroxyurs-12-en-28-oate (AUD1) and methyl 3β-acetoxyurs-12-en-28-oate (AUD2)) in a model of experimental autoimmune encephalomyelitis (EAE). EAE was induced by subcutaneous immunization of myelin oligodendrocyte glycoprotein peptide (MOG35−55) in C57BL/6 mice. On the 15th day post-induction (dpi), the mice were treated with AU, AUD1, or AUD2 (50 mg/kg intraperitoneally per day) for six days. Clinical signs were monitored until 21 dpi, and parameters were assessed in the spinal cord, lymph nodes, and brain at 21 dpi. The results showed that both derivatives similarly attenuated the clinical signs of EAE and reduced inflammation and demyelination in the spinal cord. In addition, they reduced the number of pro-inflammatory cells in the brain, the level of IL-1β, TNF, and IFN-γ in the spinal cord, and, in the periphery, promoted the regulation of pro-inflammatory cells. In conclusion, regulating cells in the periphery and reducing the number of pro-inflammatory cells in the CNS, with AUD1 and AUD2, culminated in the efficacy of the clinical parameters presented in EAE, suggesting a therapeutic potential for treating MS.